Gettman is a marijuana reform activist and head of the Coalition for Rescheduling Cannabis. A former director of the National Organization for the Reform of Marijuana Laws, he is a longtime contributor to High Times magazine, where he writes the Cannabis Column. As leader of the Bulletin of Cannabis Reform, he publishes frequently on the marijuana industry.
Medical marijuana
Gettman is a medical cannabis advocate.
Science and the End of Marijuana Prohibition
In 1999, Gettman presented a speech, Science and the End of Marijuana Prohibition, at the 12th International Conference on Drug Policy Reform. He noted that under the Controlled Substances Act, the key decision-makers on marijuana are the scientists at the United States Department of Health and Human Services, whose scientific and medical findings are binding on the Drug Enforcement Administration. Pointing out that Schedules I and II are, by law, reserved for drugs like heroin and cocaine with a "high potential for abuse," Gettman proposed that drug policy reformers use the petitioning process to "cross-examine under oath and penalty of perjury every HHS official and scientist who claims that marijuana use is as dangerous as the use of cocaine or heroin."
Petitions
In 1995 Gettman submitted a petition to the Drug Enforcement Administration calling for the rescheduling of cannabis. The petition sought to remove marijuana and its cannabinoids from Schedules I and II of the Controlled Substance Act on the grounds that the drug lacks the potential for abuse that warrants inclusion there. The DEA must by law forward all petitions which advocate the rescheduling of a drug to the Department of Health and Human Services for further review. By proceeding to do so, the DEA implicitly judged that "sufficient grounds" exist for the rescheduling of cannabis. In 1999, Gettman speculated that if removed from Schedule I, cannabis could be:
Removed from the Schedules and regulated similarly to alcoholic beverages or tobacco.
However, upon reviewing the HHS evaluation, the DEA concluded in 2001 that adequate evidence did not exist to necessitate the change. In response, Gettman brought the case before the US Court of Appeals. The court denied the case judicial review because Gettman, not a medical cannabis patient, was unharmed by the DEA restricting access to the drug. Gettman explained that apparently "only those who are actually injured by DEA's refusal to reschedule cannabis have standing to submit DEA's potential actions in this area to judicial review by the federal courts" and organized a coalition to meet this requirement for a subsequent petition. In October 2002, the Coalition for Rescheduling Cannabis filed another petition before the DEA. In April 2002, the DEA formally accepted the proposal, which sought federal recognition of the medicinal value of cannabis, reclassification of the drug, and the establishment of a legal framework for the production and distribution of medical cannabis. In doing so, the DEA acknowledged sufficient merit in the evidence presented in the petition, which focused on accepted medicinal value rather than relative harm, to warrant additional review rather than dismissal. In 2004, the DEA referred the petition to the Department of Health and Human Services for a full-scale evaluation where, as of May 2006, it remains. The Cannabis Column, a longstanding column on High Times magazine, tracks the progress of this petition. As of September 16, 2009, the column has eclipsed fifty issues.
In 2006 Gettman wrote a special report, entitled "Marijuana Production in the United States, published in the Bulletin of Cannabis Reform. In it, he estimated the monetary value of the marijuana crop and determined marijuana the largest cash crop in the nation, exceeding the combined values of corn and wheat. Gettman then argues that marijuana prohibition has failed and calls for the legalization and regulation of what he calculated to be a $35.8 billion industry.
Lost Taxes and Other Costs of Marijuana Laws
In 2007 Gettman authored another special report for the Bulletin of Cannabis Reform, entitled "Lost Taxes and Other Costs of Marijuana Laws." The study examined the effects of marijuana prohibition from an economic perspective and calculated that prohibition costs taxpayers approximately $42 billion in enforcement costs and foregone tax revenues.